5.89
5.89 (0%)
As of Feb 14, 2025
Kezar Life Sciences, Inc. [KZR]
Source:
Company Overview
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. We believe therapies that inhibit multiple drivers of disease by targeting fundamental upstream control processes within the cell have the potential for profound therapeutic benefit in a number of difficult-to-treat diseases.
| Country | United States |
| Headquarters | south san francisco, california |
| Phone Number | (650) 822-5600 |
| Industry | manufacturing |
| CEO | Christopher Kirk, Ph.D. |
| Website | www.kezarlifesciences.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-21.9 |
| Net Income | $-20.3 |
| Net Cash | $-0.6 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -24.8% |
| Profit as % of Stockholder Equity | -15.2% |
Management Effectiveness
| Return on Equity | -15.2% |
| Return on Assets | -12.4% |
| Turnover Ratio | |
| EBITA | $-21.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $164.1 |
| Total Liabilities | $30 |
| Operating Cash Flow | $-57.4 |
| Investing Cash Flow | $56.7 |
| Financing Cash Flow | $0.1 |
